Published Online: 2025 July 10

# **Research Article**



# Cutaneous Manifestations in Children with Celiac Disease

Mahsa Besharat <sup>1</sup> , Mehrdad Teimoorian <sup>2,3,\*</sup>, Mohammad Sobhani Shahmirzadi <sup>1</sup>, Ali Ghezelsefloo <sup>3,4</sup>, Alireza Niazi <sup>3,4</sup>, Amineh Kashiri <sup>5</sup>, Khatereh Shahidi <sup>4</sup>, Seyed Amirali Hoseini <sup>4</sup>, Mohammad Dadjou <sup>3</sup>

<sup>1</sup>Neonatal and Children's Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran

<sup>2</sup> Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran

<sup>3</sup> Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Golestan University of Medical Sciences, Gorgan, Iran

<sup>4</sup> Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran

<sup>5</sup> Clinical Research Development Unit (CRDU), Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran

\* Corresponding Author: Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Golestan University of Medical Sciences, Gorgan, Iran. Email: mehrdadtm@gmail.com

Received: 25 February, 2025; Revised: 26 May, 2025; Accepted: 10 June, 2025

## Abstract

**Background:** Skin manifestations are significant extra-intestinal symptoms of celiac disease (CD), and dermatologic disorders are more prevalent among CD patients than in the normal population.

**Objectives:** The present study aimed to investigate the skin manifestations in children with CD.

**Methods:** This cross-sectional study was conducted on patients under 18 years with CD registered at the Celiac Registry Center, Golestan Research Center of Gastroenterology and Hepatology, between April and July 2023. Participants were examined by a dermatologist attending the research center as scheduled. The skin manifestations were categorized according to their types, location, duration, and distribution. All data were analyzed using SPSS version 26 to show central and distributive indices. Quantitative data were reported as mean (standard deviation), and categorical data were reported as number and percent.

**Results:** A total of 39 children (53.8% female) were included in the study. The mean (SD) age of the patients was 9.84 (4.41) years. The mean (SD) duration of disease and initiation of the gluten-free diet (GFD) was 4.24 (2.64) years. Thirty-seven (94.8%) children had at least one lesion, with the most common locations being the face (16.8%) and limbs (14.4%). In examining the course of the disease, 96.4% of the patients had a chronic course, and in 15.5% of them, the distribution was symmetric. The most frequent types among 83 cutaneous findings were dry skin (20.4%), pityriasis alba (15.6%), and keratosis pilaris (12%).

**Conclusion:** Most children with CD experienced skin problems. The small sample size, lack of a validated scale for adherence to GFD, and absence of a healthy control group limited the generalizability of the findings.

Keywords: Celiac Disease, Children, Skin, Cutaneous Manifestation, Gluten

## 1. Background

Celiac disease (CD) is an autoimmune disorder characterized by small intestinal enteropathy and atrophy of intestinal villi. It occurs in individuals with a genetic predisposition and is triggered by dietary gluten (1, 2). Estimates indicate that CD affects approximately 1% of the world's population. Its prevalence is reported to be 1.4% based on positive serological tests and 0.7% based on biopsy results (3). The prevalence of CD varies by sex, age, and geographical location. Specifically, the prevalence of CD is 0.4% in South America, 0.5% in Africa and North America, 0.6% in Asia, and 0.8% in Europe and Oceania (4). However, in certain countries such as India and Iran, the prevalence of CD is higher, largely due to the substantial consumption of wheat (4). In studies conducted in Iran, the prevalence of CD was found to be 2% based on duodenal biopsy and 3% based on serological tests, both of which are higher than the global average (5).

Evidence indicates that patients with CD are more prone to other immune-mediated disorders, leading to

Copyright © 2025, Besharat et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

How to Cite: Besharat M, Teimoorian M, Sobhani Shahmirzadi M, Ghezelsefloo A, Niazi A, et al. Cutaneous Manifestations in Children with Celiac Disease. J Compr Ped. 2025; 16 (3): e160773. https://doi.org/10.5812/jcp-160773.

extra-intestinal manifestations compared to the general population (6, 7). This susceptibility is attributed to the extension of adaptive immune responses beyond intestinal tissues (8). Celiac disease is closely associated with various skin disorders, resulting in dermatological issues, including dermatitis herpetiformis (DH), psoriasis, urticaria, chronic dry skin, erythema nodosum, vitiligo, among others (9). Among these, DH and psoriasis appear to be more closely related to CD. Dermatitis herpetiformis is polymorphic, characterized by lesions that manifest as erythema, plaque, and papule on the head, face, neck, as well as the extensor surfaces of the knees, elbows, shoulders, and sacral region. Psoriasis is identified by red and dry scaly patches on the skin (9).

Although the relationship between DH and CD is well-known, other cutaneous manifestations have been poorly studied. Additionally, CD is often underdiagnosed because the classic signs and symptoms are not present in all patients. Therefore, investigating other extra-intestinal manifestations of CD can lead to a better understanding of the condition.

## 2. Objectives

In this study, we aimed to assess the presence of skin manifestations in children with CD.

#### 3. Methods

This cross-sectional study was conducted at the Celiac Registry Center, Golestan Research Center of Gastroenterology and Hepatology in Gorgan, northeast Iran, between April and July 2023. The Ethics Committee of Golestan University of Medical Sciences approved the study protocol (IR.GOUMS.REC.1402.481). Written informed consent was obtained from all patients and their parents. Registered patients were invited to participate in the study via phone call (N = 79). Among them, 39 children attended the clinic for evaluation. Inclusion criteria included a CD diagnosis confirmed by positive serology or biopsy and age below 18 years.

A full body examination was conducted by a dermatologist attending the research center as scheduled. The examination included the body, hair, and nails of the patients to detect any cutaneous manifestations. In the case of finding any lesions, patients were assessed and treated according to standard protocols by the dermatologist. Dermatologists classified the findings based on the type, location (face, limbs, head, trunk, and lumbosacral region), duration (acute, chronic, and recurrent), and distribution (symmetric or asymmetric) of the lesions.

The demographic information of patients, details of physical examinations, first anti-tissue transglutaminase antibody (anti-tTg Ab) test results, intestinal biopsy results, and other data were recorded. All data were then analyzed using SPSS version 26 to show central and distributive indices. Quantitative data were reported as mean (standard deviation), and categorical data were reported as number and percent.

## 4. Results

The mean [standard deviation (SD)] age of the patients was 9.84 (4.41) years. The mean (SD) duration of the disease and initiation of the gluten-free diet (GFD) was 4.24 (2.64) years. Five children had a positive family history of CD. The mean (SD) level of anti-tTg Ab in patients was 185.67 (161.79 IU/mL) at the time of CD diagnosis. Histopathology data were available for 31 patients, with Marsh 3b (45.2%) reported as the most common type. The clinical data of the patients are summarized in Table 1.

Cutaneous manifestations were found in 37 patients (51.3% female). Most of the children (96.4%) experienced chronic skin problems. The distribution of lesions was symmetric in 15.6% of the patients. The most commonly involved areas were the face (16.8%) and limbs (14.4%). Overall, 83 cutaneous lesions were detected. The most common types were dry skin (20.4%), pityriasis alba (15.6%), keratosis pilaris (12%), and pigmentation (10.8%). The details of dermatologic findings are presented in Table 2.

Among all the patients, 25 cases had at least two findings. Of these, the most common combinations were pityriasis alba with dry skin (9 patients) and dry skin with pigmentation (5 patients).

## 5. Discussion

Cutaneous manifestations are commonly observed in both pediatric and adult patients with CD (10). In this study, 94.8% of the CD patients experienced at least one mucocutaneous disorder. The skin diseases associated with CD are categorized into five groups (8). The first group includes allergic skin diseases, such as urticaria, chronic urticaria, and atopic dermatitis, which have been related to CD. The second group consists of inflammatory disorders, including pityriasis rubra pilaris, erythroderma, pityriasis lichenoides, and erythema nodosum, which are also found in CD patients. The third group encompasses immunemediated skin diseases, such as psoriasis, that are associated with CD. Autoimmune disorders, including alopecia areata, cutaneous vasculitis, vitiligo, and lupus

Variables	Values <sup>a</sup>
Gender	
Female	21 (53.8)
Male	18 (46.2)
Ethnicity	
Fars	17 (44.7)
Turkmen	11 (28.9)
Sistani/Balouch	10 (26.3)
Marsh classification	
1	1 (3.2)
2	3 (9.7)
3a	8 (25.8)
3b	14 (45.2)
3c	5 (12.8)
Age (y)	$9.84\pm4.41$
Disease duration (y)	$4.23\pm2.64$
Anti-tTg Ab level (IU/mL)	185.67±161.79

<sup>a</sup> Values are expressed as No. (%) or mean ± SD.

erythematosus, are more common in these patients. Lastly, the miscellaneous group includes conditions such as aphthous stomatitis and rosacea, which have also been found to be associated with CD.

In our study, inflammatory skin disorders were the most common type of cutaneous findings, which differs from previous investigations. A cohort study conducted in Sweden collected data from 43,300 CD patients over 45 years and reported an increased risk of eczema, psoriasis, urticaria, vitiligo, and alopecia areata (11). A systematic review and meta-analysis in 2016 showed that the primary cutaneous complications in CD patients included DH, alopecia areata, dermatomyositis, vitiligo, lupus erythematosus, and psoriasis (12). Additionally, another study in India found atopic dermatitis to be the most common skin disorder among children with CD (13). A study by Quratulain et al. showed that autoimmune skin disorders, including psoriasis, DH, and alopecia areata, were frequently found among the patients (14).

Most of the reported disorders were related to immune system malfunction, including allergic, immune-mediated, and autoimmune mechanisms. Several hypotheses attempt to explain this relationship. One justification for this connection is the shared genetic background and similar environmental triggers between CD and certain skin disorders (15). Another explanation involves the alteration in intestinal barrier permeability, which allows gluten to pass into the bloodstream and triggers an inappropriate immune response (16). Additionally, the release of IgE and other immunoglobulins in the submucosa of the small intestine after gluten exposure can lead to the development of urticaria and atopic dermatitis (17). Furthermore, the production of proinflammatory cytokines such as TNF- $\alpha$  and interferon gamma (IFN $\gamma$ ) has been shown to be related to immune-mediated disorders like psoriasis (18).

There have been investigations with findings similar to those of our study. These studies found that inflammatory skin complications are the most common type of cutaneous disorders in patients with CD. A study conducted by Seyhan et al. reported that xerosis and keratosis pilaris were common findings in children with CD (19). The prevalence of inflammatory disorders in CD can be explained by various mechanisms. Gluteninduced activation of T lymphocytes and the release of proinflammatory cytokines can lead to both local and systemic inflammation (20). Additionally, alteration in intestinal permeability that allows the passage of gluten may provoke the inflammatory process, potentially leading to damage in other tissues throughout the body (16). The high rate of inflammatory skin findings in CD patients may also be the result of continuous gluten exposure, even after the initiation of a GFD. Based on our clinical experience, adherence to a GFD is challenging for most patients in Iran (21). This difficulty arises partly from limited access to gluten-free foods and materials,

Dermatological Findings	No. (%)
Duration	
Acute	1(2.6)
Chronic	36 (92.3)
Recurrent	2 (5.1)
Distribution	
Symmetric	13 (33.3)
Asymmetric	26 (66.7)
Location	
Face	14 (16.8)
Trunk	7(8.4)
Limbs	12 (14.4)
Scalp	5(6)
Lumbosacral region	4 (4.8)
Nail	5(6)
Oral cavity	8 (9.6)
Hair	6 (7.2)
Гуре	
Pityriasis alba	13 (15.6)
Dry skin	17(20.4)
Keratosis pilaris	10 (12)
Acne	5(6)
Hirsutism	2 (2.4)
Seborrheic dermatitis	5(6)
Pigmentation	9 (10.8)
Nevus	2 (2.4)
Scar	1(1.2)
Freckle	1(1.2)
Food allergy	1(1.2)
Alopecia	2 (2.4)
Allergic contact dermatitis	1(1.2)
Vitiligo	1(1.2)
Oral aphthous	8 (9.6)
Paronychia	2 (2.4)
Brittle nail	2 (2.4)
Periungual hyperpigmentation	1 (1.2)

and partly from insufficient knowledge and understanding among patients about the GFD and how to incorporate it into their daily routines. Given these challenges, the high rate of inflammatory skin problems is not unexpected within the population studied.

Dry skin or xerosis is a common finding in most CD patients, including those in our study. Multiple factors can contribute to xeroderma, such as vitamin deficiencies and systemic diseases that appear to be associated with CD (22). Children with CD often face nutritional challenges and lower intakes of essential nutrients (23). Therefore, this issue can be addressed by

providing gluten-free sources or supplements to compensate for deficiencies that may be related to skin problems.

In this study, there were limitations that need to be considered. First, the sample size was limited, and a larger population could be more useful for understanding the cutaneous manifestations in CD patients. Second, we did not assess the anti-tTg level of the patients to investigate its association with skin findings and whether they had exposure to gluten. Additionally, the absence of a control group limits the interpretation of our findings specific to the cutaneous findings of CD.

## 5.1. Conclusions

Cutaneous complications are prevalent among pediatric CD patients, with dry skin, pityriasis alba, and keratosis pilaris being the most common. These findings highlight the need for systematic dermatological evaluations in CD patients to ensure timely diagnosis and management of skin-related complications. It should be kept in mind that these results may not be generalized to other populations with higher GFD adherence or different cultures or ethnicities.

## Acknowledgements

This article is extracted from a thesis for an internal specialization degree at Golestan University of Medical Sciences (GOUMS). The authors would like to thank the Research Deputy of GOUMS for their financial and administrative support throughout the project. No additional funding sources has been used.

## Footnotes

**Authors' Contribution:** Study concept and design: M. T., S. B., M. B., A. K., and M. D.; Acquisition of data: H. M., A. G., A. N., K. S., and S. H.; Analysis and interpretation of data: S. B., M. B., A. K., and M. D.; Drafting of the manuscript: A. G., A. N., K. S., and S. H.; Critical revision of the manuscript for important intellectual content: S. B., M. B., and M. T.; Statistical analysis: A. G., A. N., K. S., and S. H.; Administrative, technical, and material support: A. K., M. D., and M. T.; Study supervision: M. T., S. B., M. B., A. K., and M. D.

**Conflict of Interests Statement:** The authors declare no conflict of interests.

**Data Availability:** The dataset presented in the study is available on request from the corresponding author during submission or after publication.

**Ethical Approval:** This study is approved under the ethical approval code of IR.GOUMS.REC.1402.481.

**Funding/Support:** This study was supported by grant 113989 from Golestan University of Medical Sciences (Dr. Mahsa Besharat).

**Informed Consent:** Written informed consent was obtained from all participants.

#### References

- Amlashi FI, Norouzi Z, Sohrabi A, Shirzad-Aski H, Norouzi A, Ashkbari A, et al. A systematic review and meta-analysis for association of Helicobacter pylori colonization and celiac disease. *PLoS One*. 2021;**16**(3). e0241156. [PubMed ID: 33657108]. [PubMed Central ID: PMC7928511]. https://doi.org/10.1371/journal.pone.0241156.
- Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al. Celiac disease: a comprehensive current review. *BMC Med.* 2019;**17**(1):142. [PubMed ID: 31331324]. [PubMed Central ID: PMC6647104]. https://doi.org/10.1186/s12916-019-1380-z.
- Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global Prevalence of Celiac Disease: Systematic Review and Metaanalysis. *Clin Gastroenterol Hepatol*. 2018;16(6):823-836 e2. [PubMed ID: 29551598]. https://doi.org/10.1016/j.cgh.2017.06.037.
- Bradauskiene V, Vaiciulyte-Funk L, Martinaitiene D, Andruskiene J, Verma AK, Lima JPM, et al. Wheat consumption and prevalence of celiac disease: Correlation from a multilevel analysis. *Crit Rev Food Sci Nutr.* 2023;63(1):18-32. [PubMed ID: 34184959]. https://doi.org/10.1080/10408398.2021.1939650.
- Mohammadibakhsh R, Sohrabi R, Salemi M, Mirghaed MT, Behzadifar M. Celiac disease in Iran: a systematic review and metaanalysis. *Electron Physician*. 2017;9(3):3883-95. [PubMed ID: 28461861]. [PubMed Central ID: PMC5407219]. https://doi.org/10.19082/3883.
- Elli L, Bonura A, Garavaglia D, Rulli E, Floriani I, Tagliabue G, et al. Immunological comorbity in coeliac disease: associations, risk factors and clinical implications. *J Clin Immunol*. 2012;**32**(5):984-90. [PubMed ID: 22526595]. https://doi.org/10.1007/s10875-012-9693-0.
- Heidarpour H, Hooshmand F, Isapanah Amlashi F, Khodabakhshi B, Mahmoudi M, Amiriani T, et al. Unexpected high frequency of antithyroid peroxidase (anti-TPO) antibodies in Golestan province, Iran. *Caspian J Intern Med*. 2023;**14**(2):371-5. [PubMed ID: 37223294]. [PubMed Central ID: PMC10201118]. https://doi.org/10.22088/cjim.14.2.371.
- Rodrigo L, Beteta-Gorriti V, Alvarez N, Gomez de Castro C, de Dios A, Palacios L, et al. Cutaneous and Mucosal Manifestations Associated with Celiac Disease. *Nutrients*. 2018;10(7). [PubMed ID: 29933630]. [PubMed Central ID: PMC6073559]. https://doi.org/10.3390/nu10070800.
- Abenavoli L, Bennardo L, Nistico SP, Luzza F. From gut to skin: the association between celiac disease and cutaneous abnormalities. *Minerva Gastroenterol.* 2021;67(4):301-3. [PubMed ID: 33856145]. https://doi.org/10.23736/S2724-5985.21.02832-4.
- Abenavoli L, Proietti I, Leggio L, Ferrulli A, Vonghia L, Capizzi R, et al. Cutaneous manifestations in celiac disease. *World J Gastroenterol.* 2006;**12**(6):843-52. [PubMed ID: 16521210]. [PubMed Central ID: PMC4066147]. https://doi.org/10.3748/wjg.v12.i6.843.
- Lebwohl B, Soderling J, Roelstraete B, Lebwohl MG, Green PHR, Ludvigsson JF. Risk of skin disorders in patients with celiac disease: A population-based cohort study. J Am Acad Dermatol. 2021;85(6):1456-64. [PubMed ID: 33144153]. https://doi.org/10.1016/j.jaad.2020.10.079.
- Zhang H. The Skin of Celiac Disease: Systematic Review and Pooled Analysis. Am J Gastroenterol. 2016;111:S479-80. https://doi.org/10.14309/00000434-201610001-01097.
- Garg T, Samudrala S, Kumar P, Chander R, Sharma S. Cutaneous Manifestations in Celiac Disease: An Observational Study. Indian J Paediatr Dermatol. 2023;24(3):223-7. https://doi.org/10.4103/ijpd.j22\_22.
- Quratulain, Rind MA, Nazir M, Rind MS. Evaluate the frequency of Autoimmune Cutaneous Disorders in patients with Celiac disease. *Professional Med J.* 2019;26(12):2105-11. https://doi.org/10.29309/tpmj/2019.26.12.3216.
- Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immunemediated diseases. *Nat Rev Genet.* 2013;14(9):661-73. [PubMed ID: 23917628]. https://doi.org/10.1038/nrg3502.

- Losurdo G, Principi M, Iannone A, Amoruso A, Ierardi E, Di Leo A, et al. Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm. World J Gastroenterol. 2018;24(14):1521-30. [PubMed ID: 29662290]. [PubMed Central ID: PMC5897856]. https://doi.org/10.3748/wjg.v24.i14.1521.
- Spencer J, Sollid LM. The human intestinal B-cell response. Mucosal Immunol. 2016;9(5):1113-24. [PubMed ID: 27461177]. https://doi.org/10.1038/mi.2016.59.
- Jabri B, Sollid LM. T Cells in Celiac Disease. J Immunol. 2017;198(8):3005-14. [PubMed ID: 28373482]. [PubMed Central ID: PMC5426360]. https://doi.org/10.4049/jimmunol.1601693.
- Seyhan M, Erdem T, Ertekin V, Selimoglu MA. The mucocutaneous manifestations associated with celiac disease in childhood and adolescence. *Pediatr Dermatol.* 2007;24(1):28-33. [PubMed ID: 17300645]. https://doi.org/10.1111/j.1525-1470.2007.00328.x.
- Lundin KE, Wijmenga C. Coeliac disease and autoimmune diseasegenetic overlap and screening. Nat Rev Gastroenterol Hepatol. 2015;12(9):507-15. [PubMed ID: 26303674]. https://doi.org/10.1038/nrgastro.2015.136.
- 21. Besharat S, Amlashi FI, Nasab IS, Qadirian P, Jafari A. Adherence to the Gluten-Free Diet (GFD) in Celiac: Self-report or expert view. *Iran J Gastroenterol Hepatol.* 2021;**26**.
- 22. Askin O, Uzuncakmak TKU, Altunkalem N, Tuzun Y. Vitamin deficiencies/hypervitaminosis and the skin. *Clin Dermatol.* 2021;**39**(5):847-57. [PubMed ID: 34785012]. https://doi.org/10.1016/j.clindermatol.2021.05.010.
- Wierdsma NJ, van Bokhorst-de van der Schueren MA, Berkenpas M, Mulder CJ, van Bodegraven AA. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. *Nutrients*. 2013;5(10):3975-92. [PubMed ID: 24084055]. [PubMed Central ID: PMC3820055]. https://doi.org/10.3390/nu5103975.